JP2002523106A - 誘導的発現系 - Google Patents

誘導的発現系

Info

Publication number
JP2002523106A
JP2002523106A JP2000567726A JP2000567726A JP2002523106A JP 2002523106 A JP2002523106 A JP 2002523106A JP 2000567726 A JP2000567726 A JP 2000567726A JP 2000567726 A JP2000567726 A JP 2000567726A JP 2002523106 A JP2002523106 A JP 2002523106A
Authority
JP
Japan
Prior art keywords
expression system
adenovirus vector
receptor
expression
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000567726A
Other languages
English (en)
Japanese (ja)
Inventor
マジド、メターリ
タニア、ソール‐ギュス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of JP2002523106A publication Critical patent/JP2002523106A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000567726A 1998-08-28 1999-08-27 誘導的発現系 Pending JP2002523106A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9810842A FR2782732A1 (fr) 1998-08-28 1998-08-28 Systeme d'expression inductible
FR98/10842 1998-08-28
PCT/FR1999/002051 WO2000012741A2 (fr) 1998-08-28 1999-08-27 Systeme d'expression inductible

Publications (1)

Publication Number Publication Date
JP2002523106A true JP2002523106A (ja) 2002-07-30

Family

ID=9529972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000567726A Pending JP2002523106A (ja) 1998-08-28 1999-08-27 誘導的発現系

Country Status (6)

Country Link
EP (1) EP1108051A2 (fr)
JP (1) JP2002523106A (fr)
AU (1) AU5426299A (fr)
CA (1) CA2341775A1 (fr)
FR (1) FR2782732A1 (fr)
WO (1) WO2000012741A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3642601A (en) * 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
ATE525091T1 (de) * 2000-03-13 2011-10-15 Engene Inc Zusammensetzungen und verfahren zur regulierten proteinexpression im darm
AU2003216407A1 (en) * 2002-02-25 2003-09-09 University Of Rochester Dna construct for inducible expression of angiogenic protein and use thereof
EP1531666B1 (fr) * 2002-05-29 2013-10-23 Regeneron Pharmaceuticals, Inc. Systeme d'expression eucaryote inductible
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
PL376397A1 (en) * 2002-10-14 2005-12-27 F.Hoffmann-La Roche Ag Transplantable cell
JP4842128B2 (ja) 2003-07-21 2011-12-21 トランジェーヌ、ソシエテ、アノニム 新規多機能性サイトカイン
NZ571965A (en) 2006-03-30 2012-02-24 Engene Inc Chitosan-based nanoparticles and methods for transfecting gut cells in vivo
EP3587455A1 (fr) 2012-10-23 2020-01-01 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
WO2016081927A2 (fr) * 2014-11-21 2016-05-26 University Of Florida Research Foundation, Inc. Vecteurs viraux adéno-associés recombinés au génome modifié

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1309044C (fr) * 1987-11-09 1992-10-20 Toshiya Takano Methode de production de genes etrangers
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
FR2745008A1 (fr) * 1996-02-20 1997-08-22 Ass Pour Le Dev De La Rech En Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
CN1215432A (zh) * 1996-04-05 1999-04-28 索尔克生物学研究所 调节外源性基因在哺乳动物系统中表达的激素介导的方法及其相关产物
FR2748753B1 (fr) * 1996-05-20 1998-08-14 Transgene Sa Nouveaux vecteurs adenoviraux pour la therapie genique
WO1998037185A2 (fr) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vecteurs pour expression genique regulee

Also Published As

Publication number Publication date
FR2782732A1 (fr) 2000-03-03
AU5426299A (en) 2000-03-21
CA2341775A1 (fr) 2000-03-09
WO2000012741A3 (fr) 2000-05-04
WO2000012741A9 (fr) 2001-03-29
WO2000012741A2 (fr) 2000-03-09
EP1108051A2 (fr) 2001-06-20

Similar Documents

Publication Publication Date Title
KR102049161B1 (ko) 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
KR100470180B1 (ko) 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US6204060B1 (en) Viral vectors and line for gene therapy
JP3989541B2 (ja) 分子間相同組換えによるウイルスベクターの作製方法
AU715526B2 (en) Novel nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
AU756607B2 (en) Use of adenoviral E4 reading frames to improve expression of a gene of interest
WO1996014875A9 (fr) Nouvelles molecules d'acide nucleique comportant un antigene prostatique specifique et leurs usages
JPH10509880A (ja) 組織特異的複製のためのベクター
US20070244064A1 (en) Methods and compositions to induce antitumor response
JP4386971B2 (ja) スプライシング配列を含んでなる組換えアデノウイルスベクター
JP2001505047A (ja) 高キャパシティーアデノウイルスベクターの開発の促進に使用するためのパッケージング細胞系
JP2002523106A (ja) 誘導的発現系
AU752148B2 (en) Chimeric adenoviral vectors
JP2002330786A (ja) 抗炎症性ベクター
US20030108524A1 (en) Vectors for expressing multiple transgenes
US6110702A (en) PSA positive regulating (PSAR) sequences and uses thereof
WO2000022124A2 (fr) Procedes et compositions permettant d'induire une reponse antitumorale
WO1997035993A9 (fr) Sequences de regulation positive de l'antigene prostatique specifique et utilisations de ces sequences
JPH07298877A (ja) 組換えアデノウイルスおよびその製造方法
JP2004283183A (ja) 組換えアデノウイルス
EP1190083A2 (fr) Produits de synthese d'adn a base d'eif 4a promoteur de gene